. Author manuscript; available in PMC: 2014 Mar 28.

Published in final edited form as: Curr Respir Med Rev. 2013 Jun 1;9(3):200–210. doi: 10.2174/1573398x113099990017

Table 2. Ongoing and Completed But Unpublished Phase IIa Studies (Extended Early Bactericidal Activity 14 Day End-Point).

Drug Classes		Study	Sites	Recruitment Groups	Regimens	Primary End-Point(s)
Q		ACTG NCT01589497	S Africa	DS-TB HIV−/+(CD4>200/μl)	2 days RHZE →12 days REZ 2 days RHZE → 12 days RMZE 14 days RHZE	Rate of change in log₁₀ CFU/ml in sputum from day 2-14
D	N	Global Alliance NCT01691534	S Africa	DS-TB HIV−/+	14 days JPaZC, JPaZ, JPaC, JZC, Z, C or RHZE	Rate of change in log₁₀ CFU/ml in sputum from day 0-14
N		Global Alliance NCT00944021	S Africa	DS-TB HIV−/+(CD4>300/μl)	14 days Pa₅₀, Pa₁₀₀, Pa₁₅₀, Pa₂₀₀ or RHZE	Rate of change in log₁₀ CFU/ml in sputum from day 0-14
N		Otsuka NCT00401271	S Africa	DS-TB HIV−/+(CD4>350/μl)	14 days D₁₀₀, D₂₀₀, D₃₀₀, D₄₀₀ or RHZE	Rate of change in log₁₀ CFU/ml in sputum from day 0-14
Ox		Pfizer NCT01225640	S Africa	DS-TB HIV −/+(CD4>350/μl)	14 days Su₆₀, Su₁₂₀₀ or RHZE	Rate of change in log₁₀ CFU/ml in sputum from day 0-2
Ox		NIAID NCT01516203	S Africa	DS-TB HIV−/+(CD4>350/μl)	14 days of Po_500od, Po_500bid, Po_800bid, Po _1200bid or RHZE	Rate of change in log₁₀ CFU/ml in sputum from day 0-14
Ed		Sequella NCT01218217	S Africa	DS-TB HIV−/+(CD4>250/μl)	14 days of Sq₇₅, Sq₁₅₀, Sq₃₀₀, Sq₁₅₀R or R	Rate of change in log₁₀ CFU/ml in sputum from day 0-14

Drug classes are coded as in Table 1: Q=fluoroquinolones, D=Diarlyquinoline, N=nitroimidazopyran, Ox=Oxazolidinones, Ed=Ethylenediamines Numbers before drug regimens specify duration in months. Drugs are coded with the following initials: R=Rifampicin, H=Izoniazid, Z=Pyrazinamide, E=Ethambutol,M=Moxifloxacin, J=Bedaquiline, Pa=PA-824, C=Clofazimine, D=Delamanid, Su=Sutezolid,Sq=SQ109. Varying dosages of a drug in different arms of a trial, are indicated by a subscript next to the drug initial, bid=twice daily.